Geron (GERN) Competitors $1.29 +0.01 (+0.78%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$1.29 0.00 (0.00%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, FOLD, CLDX, MNKD, BCRX, NVAX, INVA, OPK, and DVAXShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind BioCryst Pharmaceuticals Novavax Innoviva OPKO Health Dynavax Technologies Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Do institutionals & insiders believe in GERN or ALKS? 73.7% of Geron shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 7.4% of Geron shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, GERN or ALKS? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M10.69-$174.57M-$0.13-9.92Alkermes$1.56B3.28$367.07M$2.0814.88 Do analysts rate GERN or ALKS? Geron presently has a consensus target price of $3.79, indicating a potential upside of 193.47%. Alkermes has a consensus target price of $42.00, indicating a potential upside of 35.70%. Given Geron's higher probable upside, equities analysts plainly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Is GERN or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Geron's net margin of -53.52%. Alkermes' return on equity of 24.86% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -31.37% -16.01% Alkermes 23.15%24.86%17.14% Which has more risk and volatility, GERN or ALKS? Geron has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Does the media favor GERN or ALKS? In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 5 mentions for Alkermes and 1 mentions for Geron. Geron's average media sentiment score of 0.67 beat Alkermes' score of 0.51 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Geron on 12 of the 17 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$816.66M$3.35B$6.11B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-9.9221.4185.8226.85Price / Sales10.69466.25616.35135.13Price / CashN/A47.6737.7861.77Price / Book2.8010.0613.236.70Net Income-$174.57M-$52.22M$3.30B$276.44M7 Day Performance-8.51%4.25%3.91%2.48%1 Month Performance-5.84%12.50%8.38%8.79%1 Year Performance-69.79%26.68%88.63%34.41% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.0603 of 5 stars$1.29+0.8%$3.79+193.5%-68.9%$816.66M$76.99M-9.9270ALKSAlkermes4.5021 of 5 stars$27.13-2.4%$41.85+54.2%+11.4%$4.59B$1.56B13.041,800LGNDLigand Pharmaceuticals4.0024 of 5 stars$166.76-1.3%$176.50+5.8%+78.5%$3.31B$167.13M-41.6980FOLDAmicus Therapeutics4.3695 of 5 stars$8.32-0.4%$15.78+89.6%-20.2%$2.57B$528.29M-69.33480CLDXCelldex Therapeutics2.1608 of 5 stars$25.25-1.4%$46.13+82.7%-13.8%$1.70B$7.02M-8.39150Positive NewsMNKDMannKind4.0574 of 5 stars$5.33flat$11.17+109.5%-10.9%$1.64B$285.50M48.46400News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.0137 of 5 stars$7.65-1.5%$16.70+118.3%-6.6%$1.63B$450.71M-42.50530NVAXNovavax4.2938 of 5 stars$8.34-3.5%$14.29+71.3%-29.2%$1.40B$682.16M3.661,990INVAInnoviva4.7737 of 5 stars$18.57-2.0%$42.75+130.2%-12.9%$1.19B$358.71M59.91100News CoverageOPKOPKO Health4.2808 of 5 stars$1.43-3.4%$2.63+83.6%+6.2%$1.17B$713.10M-5.722,997DVAXDynavax Technologies4.5976 of 5 stars$9.73-2.3%$24.33+150.1%-5.8%$1.17B$277.25M-21.15350Positive News Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors CLDX Competitors MNKD Competitors BCRX Competitors NVAX Competitors INVA Competitors OPK Competitors DVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
